PRNewsWire
10 Aug 2026, 11:30 UTC · 2h ago
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
10 Aug 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Jazz gains ABS-1230, a potential first-in-class therapy for KCNT1+ epilepsy, which currently has no FDA-approved treatments. — Entering an untapped market with a potential first-in-class drug for a high-unmet-need condition provides substantial long-term revenue potential.
+0.60Jazz Pharmaceuticals is acquiring Actio Biosciences for an upfront payment of $820 million and up to $500 million in contingent milestones. — A significant capital expenditure for a strategic acquisition usually signals confidence in a pipeline asset, though the immediate cash outflow is a headwind.
+0.40ABS-1230 has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program and holds Fast Track and Orphan Drug designations. — Regulatory designations and inclusion in RDEP reduce time-to-market and lower the risk of clinical development failure.
+0.30Continue reading
6 related stories
Search tags
Jazz will receive a minority stake in a new spin-out entity focused on other genetic rare neurological diseases, including a TRPV4 inhibitor. — This provides Jazz with optionality and exposure to additional rare disease pipelines without the full cost of acquisition.
+0.20Which stocks this story touches
The company is strategically expanding its rare epilepsy portfolio through the acquisition of a potential first-in-class therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
2h ago
